The Experimental Medicine and Industry Partnership (EMIP) has been established at the Oxford Health BRC to support commercial organisations who are looking to implement experimental medicine approaches in their psychiatric treatment development programmes.
The BRC partners – Oxford University and Oxford Health NHS Foundation Trust – are home to some of the world’s leading basic, clinical and translational neuroscience researchers, with expertise and experience that are critical for the effective application of experimental medicine approaches to psychiatric drug development programmes. They have an established track record of successful collaboration with industry and facilitating the successful translation of evidence from preclinical models to early clinical trials.
Human neurocognitive mechanistic markers of psychiatric drug action developed in Oxford have been implemented across the world in early phase clinical trials in order to:
- Screen and predict the effects of novel candidate treatments prior to large scale efficacy testing
- De-risk compound development
- Facilitate decision making and improve subsequent trial design
- Predict treatment response
What does EMIP do?
The EMIP provides tailored peer review of experimental medicine clinical development strategies and advice on how to optimise the application of human models and biomarkers to psychiatric drug development, drawing on Oxford’s expertise in cognitive neuroscience, pharmacology, neurostimulation, neuroimaging, sleep, digital wearables, drug repurposing, psychological treatment, lifestyle interventions, gut health and precision psychiatry.
Outcomes from our consultation process can include:
- Assisting with the application of validated experimental medicine approaches in treatment development for psychiatry
- Support with project/programme development and delivery locally or through national or international networks
- Sign-posting to commercial or academic partners who would be best placed to deliver the proposed suggestions
- Assisting with the development of funding proposals for submission to grant/governmental funding bodies or investors
For more information about EMIP, or to make an initial enquiry please contact Dr Susannah Murphy
AIMday in Experimental Medicine in Psychiatry
The EMIP was launched with an AIMday in Experimental Medicine in Psychiatry industry event on Wednesday 7 July. The AIMday format allows industry to propose challenges for one-hour roundtable discussions with groups of relevant academics and clinicians from Oxford. You can read a selection of blogs from the AIMday sessions in the collection below.